Exploring new treatment options for breast cancer
New therapeutic vulnerabilities in breast cancer
This study is looking at how breast cancer can become resistant to current treatments and aims to find new ways to fight it, so that patients can have better options in the future.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10876966 on NIH RePORTER |
What this research studies
This research focuses on understanding how breast cancer develops resistance to existing therapies and aims to identify new therapeutic targets and combination treatments. A consortium of three research groups in Boston collaborates to translate their preclinical findings into clinical applications, potentially leading to new FDA-approved therapies. The project involves advanced techniques like ATAC sequencing and CRISPR-based screens to uncover the biological mechanisms at play in breast cancer. Regular meetings and retreats foster collaboration among researchers and trainees to enhance the research process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer, particularly those who have not responded well to current therapies.
Not a fit: Patients with non-breast cancer conditions or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for breast cancer, improving patient outcomes.
How similar studies have performed: Previous research in this area has shown promise, with some findings already leading to FDA-approved treatments and ongoing clinical trials.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Polyak, Kornelia — Dana-Farber Cancer Inst
- Study coordinator: Polyak, Kornelia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.